Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.63 |
| ▸ | LCK | P06239 | 4/20 | 0.63 |
| ▸ | CSF1R | P07333 | 2/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113564 | 0.91 | MAPK14 (0.61) | MAPK14LCKCSF1RMAP2K1KDR | |
| SCHEMBL14078280 | 0.83 | MAPK14 (0.66) | MAPK14LCKCSF1RMAP2K1KDR | |
| SCHEMBL5110981 | 0.82 | HTR1D (0.54) | MAPK14LCKCSF1RHTR1DSLC6A4 | |
| SCHEMBL5123347 | 0.77 | MAPK14 (1.00) | MAPK14LCKCSF1RMAP2K1KDR | |
| SCHEMBL5124039 | 0.77 | MAPK14 (0.63) | MAPK14LCKCSF1RMAP2K1KDR | |
| SCHEMBL14078277 | 0.76 | MAPK14 (0.68) | MAPK14LCKCSF1RMAP2K1KDR | |
| SCHEMBL5117599 | 0.75 | MAPK14 (0.64) | MAPK14LCKCSF1RMAP2K1KDR | |
| SCHEMBL5124496 | 0.74 | MAPK14 (0.57) | MAPK14LCKCSF1RKMT2A | |
| SCHEMBL5123466 | 0.74 | MAPK14 (0.72) | MAPK14LCKCSF1RMAP2K1KDR | |
| SCHEMBL5122976 | 0.73 | MAPK14 (0.62) | MAPK14LCKCSF1RMAP2K1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1499600-B1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 8/4885LCK 141/4885CSF1R 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.